Camlin Fine Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021
May 29, 2021 at 08:13 pm IST
Share
Camlin Fine Sciences Limited announced earnings results for the fourth quarter ended March 31, 2021. For the fourth quarter, the company announced total revenue was INR 3,287.171 million compared to INR 2,956.409 million a year ago. Net income was INR 142.653 million compared to INR 26.721 million a year ago. Basic earnings per share from continuing operations was INR 1.16 compared to INR 0.22 a year ago. Diluted earnings per share from continuing operations was INR 1.03 compared to INR 0.22 a year ago. For the full year, total revenue was INR 11,920.873 million compared to INR 10,525.768 million a year ago. Net income was INR 509.634 million compared to INR 303.186 million a year ago. Basic earnings per share from continuing operations was INR 4.13 compared to INR 2.5 a year ago. Diluted earnings per share from continuing operations was INR 3.68 compared to INR 2.5 a year ago.
Camlin Fine Sciences Limited is an India-based company, which is engaged in research, development, manufacturing and marketing of specialty chemicals, ingredients, and additive blends. The Company is a provider of diverse advanced antioxidants and shelf-life extensions, aroma ingredients, performance chemical products and related solutions for food, animal nutrition, pet food, pharmaceutical and petrochemical industries globally. Its products include TBHQ, Catechol, BHA, 4-Tertiary Butyl Catechol, Xtendra, Butylated Hydroxy Toluene, Guaiacol, Para DiMethoxy Benzene, NaSure, MEHQ, Ascorbyl Palmitate, and HQEE. The Company manufactures specialty chemicals that can be categorized into shelf-life solutions, performance chemicals, aroma ingredients and health and wellness. Its products are used in varied industries, such as human food, animal feed, pet food, agrochemicals, petrochemicals, pharmaceuticals, nutraceuticals, flavors and fragrances and health care.